ENSG · Ensign Group, Inc
$171.78
+2.15 (+1.27%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$10.21B
Shares
58.28M
Volume · Oct 2
327.8K
Avg daily vol (3M)
387.07K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$169.63
Open$172.34
Day$168.46–174.16
52W close$147.13–215.83
Avg vol 30d344K
Short int1.5M · 2.6% float · 4.6d
Short vol39%
Last earningsJul 29, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 27
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 4 wks
filed Jul 27, 2026
call held Jul 29, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$5.49B
Trailing 12 months
Net income (TTM)
$378.70M
Trailing 12 months
Revenue growth YoY
+17.3%
Year over year
Operating margin
8.5%
Trailing 12 months
P / E (TTM)
26.6
Trailing earnings · reciprocal yield 3.8%
FCF yield
—
TTM · current market cap
Return on invested capital
15.7%
Trailing 12 months
Net cash
$181.10M
Latest balance sheet
Dividend yield
0.0%
Trailing 12 months
Shares change YoY
+1.5%
Year over year · more shares
Price change (1Y)
-2.8%
Trailing year
Short interest
2.6%
Latest settlement · 4.6 days to cover
AI Brief
Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26
TL;DR. Ensign reported record Q2 2026 results with adjusted EPS of $1.92 (+20.8% YoY) and raised its full-year 2026 earnings guidance to $7.75–$7.85 per diluted share and revenue guidance to $5.87–$5.92 billion, driven by occupancy gains, skilled mix expansion, and continued acquisitions.
Bullish
- + Raised full-year 2026 EPS guidance to $7.75–$7.85 from $7.48–$7.62 and revenue guidance to $5.87–$5.92 billion from $5.81–$5.86 billion.
Bearish
- − Recently acquired Texas facilities carry higher purchase prices, lower-than-average occupancies, and 'significant clinical and operational hurdles' that will take time to deliver expected returns.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−4%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
33%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−15%
trailing
YTD return
−3%
this year
Relative strength
−27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $177 › 200d $182 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +84 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.58% of float · ▲ +1.9% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
556 holders — mid 3-yr range
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
+19%
Y/Y
EPS growth
+14%
Y/Y
Free cash flow
$492.7M
Valuation
P/E 27.5
rich
Buyback
$60.0M
remaining
Balance sheet
$362.1M
net cash
Quant / Vol
risk profile
Volatility
28%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
2.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 27, 2026
Revenue
· annual 2026
Initiated
$5.87B – $5.92B
prior FY $5.06B
midpoint +16.6% Y/Y
Guided vs delivered
· last 7 settled
Annual revenue guidance
annual 2024
guided $4.2B – $4.22B
$4.26B
Beat +1.2%
Diluted earnings per share
annual 2023
guided $4.73 – $4.79
$3.65
Miss −23.3%
Annual revenue
annual 2023
guided $3.72B – $3.73B
$3.73B
In line
Earnings per diluted share
annual 2021
guided $3.60 – $3.68
$3.42
Miss −6.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
33%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $177 › 200d $182 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +84 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.58% of float · ▲ +1.9% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
556 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $147
Now $170 · 33%
Range high $216
vs 200-day avg -7%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Actual patient days | 3,017,641 | three months ended June 30, 2026 filing | — |
| Actual patient days - Recently Acquired Facility | 447,826 | three months ended June 30, 2026 filing | — |
| Actual patient days - Same Facility | 2,164,347 | three months ended June 30, 2026 filing | — |
| Actual patient days - Transitioning Facility | 405,468 | three months ended June 30, 2026 filing | — |
| Adjusted Earnings Per Share non-GAAP | $1.92 | Three Months Ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $181.15M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP EBITDA $162.28M
+$16.17M Stock-based compensation expense
+$2.18M Costs incurred related to system implementations
+$0K Loss (gain) on long-lived assets and business interruption recoveries
+$519K Acquisition related costs
= Adjusted EBITDA $181.15M
|
|||
| Adjusted EBITDAR non-GAAP | $247.56M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Adjusted EBITDA $181.15M
+$66.41M Rent—cost of services
= Adjusted EBITDAR $247.56M
|
|||
| Adjusted EBT non-GAAP | $152.54M | Three Months Ended June 30, 2026 filing | — |
| Adjusted Net Income non-GAAP | $114.31M | Three Months Ended June 30, 2026 filing | — |
| Dollar value of common stock repurchased | $40M | three months ended June 30, 2026 filing | — |
| EBITDA non-GAAP | $162.28M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income $99.83M
-$96K Less: Net income attributable to noncontrolling interests
-$4.63M Less: Interest income
+$33.84M Add: Provision for income taxes
+$31.41M Add: Depreciation and amortization
+$1.93M Add: Interest expense
= EBITDA $162.28M
|
|||
| FFO non-GAAP | $24.75M | three months ended June 30, 2026 filing | — |
| FFO for Standard Bearer non-GAAP | $24.75M | Three Months Ended June 30, 2026 filing | — |
| Number of campuses at period end | 32 | Three Months Ended June 30, 2026 filing | — |
| Number of facilities at period end | 348 | Three Months Ended June 30, 2026 filing | — |
| Number of facilities at period end - Recently Acquired Facility | 64 | three months ended June 30, 2026 filing | — |
| Number of facilities at period end - Same Facility | 234 | three months ended June 30, 2026 filing | — |
| Number of facilities at period end - Transitioning Facility | 50 | three months ended June 30, 2026 filing | — |
| Occupancy percentage — Operational beds | 82.9% | three months ended June 30, 2026 filing | — |
| Occupancy percentage — Operational beds - Recently Acquired Facility | 76.6% | three months ended June 30, 2026 filing | — |
| Occupancy percentage — Operational beds - Same Facility | 84.1% | three months ended June 30, 2026 filing | — |
| Occupancy percentage — Operational beds - Transitioning Facility | 84.7% | three months ended June 30, 2026 filing | — |
| Other third-party rental income | $3.56M | the three months ended June 30, 2026 filing | +56.5% |
|
|
|||
| Pennant rental income | $4.43M | the three months ended June 30, 2026 filing | +8.5% |
|
|
|||
| Same Facilities occupancy | 84.1% | the three months ended June 30, 2026 filing | — |
| Shares of common stock repurchased | 257K | three months ended June 30, 2026 filing | — |
| Skilled Mix (Days) | 31% | Three Months Ended June 30, 2026 filing | — |
| Skilled Mix (Revenue) | 50% | Three Months Ended June 30, 2026 filing | — |
| Skilled mix by nursing days - Recently Acquired Facility | 26.9% | three months ended June 30, 2026 filing | — |
| Skilled mix by nursing days - Same Facility | 32.2% | three months ended June 30, 2026 filing | — |
| Skilled mix by nursing days - Transitioning Facility | 29.7% | three months ended June 30, 2026 filing | — |
| Skilled mix by nursing revenue - Recently Acquired Facility | 45.1% | three months ended June 30, 2026 filing | — |
| Skilled mix by nursing revenue - Same Facility | 51% | three months ended June 30, 2026 filing | — |
| Total rent expense under the Master Leases | $19.76M | the three months ended June 30, 2026 filing | +16.9% |
|
|
|||
| Total rental income from third-party sources | $7.98M | the three months ended June 30, 2026 filing | +25.6% |
|
|
|||
| Total rental revenue | $44.13M | three months ended June 30, 2026 filing | +40.2% |
|
|
|||
| Total skilled nursing revenue - Average daily revenue rate | $435.1 | three months ended June 30, 2026 filing | — |
| Transitioning Facilities occupancy | 84.7% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENSG
this stock
Ensign Group, Inc
|
$10.21B | -2.6% | +18.7% | 27.5 | 2.6% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -9.3% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.1% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +27.8% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +12.2% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENSG | -2.1% | -1.8% | -14.8% | -1.4% | -2.6% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -1.7% | -1.6% | -27.2% | -1.6% | -14.7% |
Capital returns
Latest dividend
$0.065
/ share · ex Sep 30, 2026
Paid (TTM)
$0.065
/ share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Buyback program
· as of Jun 30, 2026
Authorized
$60.00M
Spent (derived)
$0
Remaining
$60.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1125376
CUSIP
29358P101
13F (30d)
14 filings
14 filers
Visit website
Investor relations